| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-01-11 | rosmantuzumab - OMP-131R10 (anti-RSPO3 antibody) | advanced refractory solid tumors, metastatic colorectal cance | 1 | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-01-08 | rosmantuzumab - OMP-131R10 (anti-RSPO3 antibody) | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology | ||
| 2016-01-07 | BIND-014 (docetaxel encapsulated in a polymeric nanoparticle) | metastatic castrate-resistant prostate cancer | 2 | Bind Therapeutics (USA - MA) | Cancer - Oncology |
| 2016-01-07 | daratumumab | multiple myeloma patients who have received at least three different lines of therapy including both a proteasome inhibitor and an immunomodulatory agent (IMiD) or who are double refractory to a proteasome inhibitor and an IMiD | 2 | Janssen Biotech, a J&J company (USA - NJ) Genmab (Denmark) | Cancer - Oncology - Rare diseases |
| 2016-01-07 | 99mTc-MIP-1404 | prostate cancer | 3 | Progenics Pharmaceuticals (USA - NY) | Cancer - Oncology - Diagnostic |
| 2016-01-07 | Traumakine® - FP-1201 (human recombinant interferon-beta 1a) | acute respiratory distress syndrome (ARDS) | 2 | Faron Pharmaceuticals (Finland) Maruishi Pharmaceutical (Japan) | Lung diseases - Respiratory diseases - Rare diseases |
| 2016-01-07 | ARC-520 | hepatitis B | 2b | Arrowhead Research Corporation (USA - CA) | Infectious diseases |
| 2016-01-06 | SENS-218 | acute or chronic inner ear lesions either from vestibular or cochlear lesions | 1 | Sensorion (France) | Otorhinolaryngology |
| 2016-01-06 | Baxdela® (delafloxacin) | community-acquired bacterial pneumonia (CABP) | 3 | Melinta Therapeutics (USA - CT) | Infectious diseases |
| 2016-01-06 | Ruconest® (C1 Esterase Inhibitor or rhC1INH - conestat alfa) | attack prophylaxis in patients with hereditary angioedema (HAE) | 2 | Pharming (The Netherlands) - Salix Pharmaceuticals (USA - NC) | Rare diseases - Genetic diseases - Hematological diseases |
| 2016-01-06 | pamrevlumab (FG-3019) | Duchenne muscular dystrophy | 2 | FibroGen (USA - CA) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2016-01-06 | NBS20 -CLBS20 - (eltrapuldencel-T) | stage III recurrent or stage IV metastatic melanoma | 3 | NeoStem (USA - NY) | Cancer - Oncology |
| 2016-01-05 | Baremsis™ - APD421 (amisulpride - intravenous formulation of a currently marketed dopamine D2 antagonist for the new use of prevention and treatment of nausea & vomiting) | prevention of post-operative nausea & vomiting (PONV) in high-risk patients | 3 | Acacia Pharma (UK) | Gastrointestinal diseases - Digestive diseases |
| 2016-01-05 | NBTXR3 | preclinical | Nanobiotix (France) | Cancer - Oncology | |
| 2016-01-05 | simtuzumab | idiopathic pulmonary fibrosis (IPF) | 2 | Gilead Sciences (USA - CA) | Lung diseases - Respiratory diseases - Rare diseases |
| 2016-01-05 | simtuzumab | idiopathic pulmonary fibrosis (IPF) | 2 | Gilead Sciences (USA - CA) | Lung diseases - Respiratory diseases - Rare diseases |
| 2016-01-04 | NBTXR3 | prostate cancer | 1-2 | Nanobiotix (France) | Cancer - Oncology |
| 2015-12-30 | tazemetostat - EPZ-6438 (E7438) | genetically defined tumors including INI1-negative tumors, certain SMARCA4-negative tumors and synovial sarcomas | 2 | Epizyme (USA - MA) Eisai (Japan) | Cancer - Oncology |
| 2015-12-23 | TG4010 (MVA-MUC1-IL2) | advanced non-small cell lung cancer | 2b-3 | Transgene (France) | Cancer - Oncology |
| 2015-12-23 | Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) | relapsed or refractory CD30-expressing non-Hogkin lymphoma | 1-2a | Seattle Genetics (USA - WA) BMS (USA - NY) | Cancer - Oncology |
